Cambium Networks Corporation (Nasdaq: CMBM), a technology company, has adjusted its third-quarter 2023 revenue expectations to between $40.0 million and $45.0 million, a substantial shift from the previous outlook of $62.0 million to $70.0 million. This adjustment contrasts with the consensus revenue estimate of $64.18 million. 

$CMBM was trading at $6.41 after-hours, reflecting a decrease of $1.51 (-19.13%).

Separately, The Clorox Company (NYSE: CLX), a consumer goods company, has provided preliminary financial information in the aftermath of a cybersecurity attack that impacted its operations. Clorox now anticipates a first-quarter fiscal 2024 adjusted loss ranging from $(0.40) to $(0.00), in stark contrast to the consensus earnings per share (EPS) estimate of $1.36. 

In after-hours, $CLX was trading at $127.74, down $4.09 (-3.10%).

Finally, MaxCyte, Inc. (Nasdaq: MXCT), a biotechnology company, has revised its revenue projection for the third quarter of 2023 to a range of $7.8 million to $8.0 million, significantly below the consensus revenue estimate of $11.35 million for the period. 

$MXCT was trading at $2.68 in the extended session, marking a decline of $0.59 (-18.04%).

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)